Today Atropos Health, a company that translates real-world clinical data into high-quality personalized and real-world evidence for care, announced a $33 million Series B funding round. This funding round was led by Valtruis, with participation from new strategic investors, including McKesson Ventures, Cencora Ventures, Sanofi Ventures, and Merck GHI Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.
This funding news comes on the heels of the company seeing rapid adoption of its Generative AI (GenAI) platform (GENEVA OS) by healthcare institutions, data companies, research institutions, etc. Atropos Health was launched in 2019 as part of a research project at Stanford University by Brigham Hyde, Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar, M.D., Ph.D., three leaders in applications of AI and Real-world Evidence Research in Healthcare, who were on a mission to democratize access to real-world evidence and quality data for improving decision making in healthcare. Since then, the company has emerged as a leader in GenAI due to unique user experiences like ChatRWD – which reduces the time needed to produce publication-grade real-world evidence from months to minutes through a chat-based AI co-pilot.
Atropos Health plans to further its stake in value-based care with this funding round. And the company’s portfolio of evidence-generating applications supports whole-person care and value-based performance and has long been utilized by the company’s customers, including Arcadia. With Atropos Health, healthcare organizations can accelerate appropriate clinical decision-making to drive low-cost patient care based on their unique physiology. Atropos Health also welcomed value-based care veteran Mike Spadafore to its board to drive this goal further.
KEY QUOTES:
“As excitement over the application of Generative AI technology in healthcare turns from potential to practical applications, the focus of providers, life sciences, and other healthcare stakeholders turns to quality, transparency, and automation backed by tangible ROI. For decades, high quality evidence has served as the currency of value in healthcare, and Atropos Health is built on a decade of investment in scaling the production of high quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities. This funding, which includes multiple major strategic stakeholders in the healthcare ecosystem, is validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data, and the critical evidence needed to better inform care, research, and policy. We’re excited to welcome these new partners to the Atropos Health family as we scale our operations, double down behind key partnerships and channels, and continue to build new products that are setting the standard for quality evidence generation and automated user experiences.”
- Brigham Hyde, CEO and Co-Founder of Atropos Health
“For nearly 15 years, I’ve had a front-row seat to value-based care’s positive impact on patients, physicians, and communities. I am excited about Atropos Health and its ability to automate personalized, evidence-based medicine at scale. Atropos can potentially improve clinician decision-making and patient outcomes, especially for high-risk, high-cost, complex patients. I believe this is a critical next step for value-based care. I’m looking forward to partnering with them.”
- Mike Spadafore, Managing Director of Valtruis
